{"id":31888,"date":"2025-04-16T11:37:02","date_gmt":"2025-04-16T03:37:02","guid":{"rendered":"https:\/\/flcube.com\/?p=31888"},"modified":"2025-04-16T11:37:03","modified_gmt":"2025-04-16T03:37:03","slug":"accuredit-therapeutics-reports-positive-24-week-data-for-art002-in-hefh-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31888","title":{"rendered":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients"},"content":{"rendered":"\n<p>Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (&gt;6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.<\/p>\n\n\n\n<p><strong>ART002: Mechanism and Innovation<\/strong><br>ART002 is the world&#8217;s first in vivo PCSK9 gene editing product designed to safely achieve saturation efficacy. The therapy delivers sgRNA and Cas9 mRNA targeting human PCSK9 via lipid nanoparticles (LNPs), specifically knocking out the PCSK9 gene in liver cells. This mechanism significantly reduces PCSK9 protein expression, blocking its interaction with LDL receptors (LDLR), reducing LDLR degradation, and lowering plasma LDL-C levels.<\/p>\n\n\n\n<p><strong>Clinical Data Highlights<\/strong><br>According to 24-week clinical data, ART002 demonstrated a mean LDL-C reduction of 56% in refractory HeFH patients, with some individuals experiencing a maximum decrease of up to 70%. The average reduction in LDL-C was 3.9 mM, exceeding the average baseline level of similar international gene editing products (3.6 mM). Notably, none of the ART002 subjects required concurrent high-intensity statin therapy, compared to 64% of subjects in international trials of similar products. Additionally, the average reduction in plasma PCSK9 protein in the high-dose group reached nearly 90%, surpassing the latest data from inclisiran (60%\u201370%) and similar international products (60%).<\/p>\n\n\n\n<p><strong>Safety Profile<\/strong><br>No dose-limiting toxicity events or other adverse events of concern were observed across all dose groups of ART002, underscoring its excellent safety profile. These results position ART002 as a potentially transformative therapy for patients with HeFH, offering significant improvements over existing treatment options.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31889,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[286,17,66],"class_list":["post-31888","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-accuredit-therapeutics","tag-clinical-trial-results","tag-gene-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (&gt;6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31888\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients\" \/>\n<meta property=\"og:description\" content=\"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (&gt;6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31888\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T03:37:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T03:37:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients\",\"datePublished\":\"2025-04-16T03:37:02+00:00\",\"dateModified\":\"2025-04-16T03:37:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1602.webp\",\"keywords\":[\"AccurEdit Therapeutics\",\"Clinical trial results\",\"Gene therapy\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31888#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31888\",\"name\":\"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1602.webp\",\"datePublished\":\"2025-04-16T03:37:02+00:00\",\"dateModified\":\"2025-04-16T03:37:03+00:00\",\"description\":\"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (>6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31888\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31888#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (>6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31888","og_locale":"en_US","og_type":"article","og_title":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients","og_description":"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (>6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.","og_url":"https:\/\/flcube.com\/?p=31888","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T03:37:02+00:00","article_modified_time":"2025-04-16T03:37:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31888#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31888"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients","datePublished":"2025-04-16T03:37:02+00:00","dateModified":"2025-04-16T03:37:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31888"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","keywords":["AccurEdit Therapeutics","Clinical trial results","Gene therapy"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31888#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31888","url":"https:\/\/flcube.com\/?p=31888","name":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31888#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31888#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","datePublished":"2025-04-16T03:37:02+00:00","dateModified":"2025-04-16T03:37:03+00:00","description":"Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for its investigator-initiated trial (IIT) of ART002 in patients with ultra-high baseline levels of low-density lipoprotein cholesterol (LDL-C) (>6 mM). The study evaluates the LNP-based in vivo gene editing drug in patients with heterozygous familial hypercholesterolemia (HeFH), showing promising results in reducing LDL-C levels.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31888#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31888"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31888#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","width":1080,"height":608,"caption":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31888#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31888"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31888\/revisions"}],"predecessor-version":[{"id":31890,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31888\/revisions\/31890"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31889"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}